JP2014005265A5 - - Google Patents

Download PDF

Info

Publication number
JP2014005265A5
JP2014005265A5 JP2012195912A JP2012195912A JP2014005265A5 JP 2014005265 A5 JP2014005265 A5 JP 2014005265A5 JP 2012195912 A JP2012195912 A JP 2012195912A JP 2012195912 A JP2012195912 A JP 2012195912A JP 2014005265 A5 JP2014005265 A5 JP 2014005265A5
Authority
JP
Japan
Prior art keywords
cancer
deuterium
hydrogen
compound
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012195912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014005265A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014005265A publication Critical patent/JP2014005265A/ja
Publication of JP2014005265A5 publication Critical patent/JP2014005265A5/ja
Pending legal-status Critical Current

Links

JP2012195912A 2012-06-22 2012-09-06 ピラゾール置換アミノ−ヘテロアリール化合物の誘導体 Pending JP2014005265A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261663221P 2012-06-22 2012-06-22
US61/663,221 2012-06-22
US201261680885P 2012-08-08 2012-08-08
US61/680,885 2012-08-08

Publications (2)

Publication Number Publication Date
JP2014005265A JP2014005265A (ja) 2014-01-16
JP2014005265A5 true JP2014005265A5 (OSRAM) 2015-10-01

Family

ID=49892488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012195912A Pending JP2014005265A (ja) 2012-06-22 2012-09-06 ピラゾール置換アミノ−ヘテロアリール化合物の誘導体

Country Status (2)

Country Link
JP (1) JP2014005265A (OSRAM)
CN (1) CN103509008A (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
CN104650049B (zh) * 2013-08-28 2018-06-08 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
WO2017088784A1 (zh) * 2015-11-27 2017-06-01 正大天晴药业集团股份有限公司 氘修饰的Brigatinib衍生物、含有该化合物的药物组合物及其用途
WO2017148325A1 (zh) 2016-03-03 2017-09-08 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN114437058A (zh) * 2020-10-30 2022-05-06 珠海宇繁生物科技有限责任公司 氘代hpk1激酶抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2373A (en) * 2004-08-26 2012-03-07 Pfizer Enantiomerically pure aminoheteroaryl compounds asprotein kinase inhibitors.
BRPI0619424B1 (pt) * 2005-12-05 2022-02-08 Pfizer Products Inc Uso de inibidores c-met/hgfrs para a fabricação de medicamentos
CN101967140A (zh) * 2010-09-14 2011-02-09 郑州泰基鸿诺药物科技有限公司 氘代克里唑蒂尼及其衍生物、制备方法和应用

Similar Documents

Publication Publication Date Title
RU2014102935A (ru) Кризотиниб для применения в лечении рака
JP2014005265A5 (OSRAM)
JP2020105190A5 (OSRAM)
RU2016108667A (ru) Комбинированная терапия для лечения рака
JP2018510850A5 (OSRAM)
JP2007153894A5 (OSRAM)
RU2008122471A (ru) Способ лечения аномального роста клеток
TR201800962T4 (en) CDC7 KINAZI INHIBITORS AND THEIR USAGE
RU2017139515A (ru) Фармацевтически активные соединения в качестве ингибиторов рецепторной тирозинкиназы семейства там
HRP20201334T1 (hr) Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
JP2011515397A5 (OSRAM)
JPWO2019150305A5 (OSRAM)
RU2010121647A (ru) Полиморфы ингибитора c-met/hgfr
RU2020142739A (ru) Ингибиторы mdm2 и их комбинации
JP2011516426A5 (OSRAM)
JP2008521928A5 (OSRAM)
JP2014514317A5 (OSRAM)
ME00937B (me) Kombinovane terapije koje sadrže hinoksalinske inhibitore pi3k-alfa za upotrebu u liječenju kancera
JP2015232006A5 (OSRAM)
JP2018529633A5 (OSRAM)
JP2010501572A5 (OSRAM)
RU2018100142A (ru) Гетероциклические соединения, эффективные для ингибирования киназы
RU2007110480A (ru) Терапевтические комбинации, содержащие ингибитор поли(адф-рибоза)полимеразы
JP2007530526A5 (OSRAM)
JP2017516784A5 (OSRAM)